Results of International, Double-Blind, Randomized, Placebo-Controlled, Phase IIa Study of Interleukin-1 Blockade With RPH-104 (Goflikicept) in Patients With ST-Segment-Elevation Myocardial Infarction (STEMI).

Competing Interests: The authors listed the following disclosures: A.A., Implicit Biosciences and Kiniksa Pharmaceuticals (consulting); B.V.T., Implicit Bioscience LLC (consulting), R-Pharm, NovoNordisk, abd Novartis (research grant); V.B., Cromos Pharma (owner); D.V. Pevsner, Boston Scientific (consulting, research grant, lectures fee), R-Pharm (research grant), Novartis (research grant, travel grant); P.C.C., SOBI, Kiniksa, and CardiolRx (consulting), Kiniksa and Novartis (research grant); D.V. Privalov, R-Pharm, Covance (EMPACT–MI), CSL Behring LLC (AEGIS-II—research grant); A.T., Boston Scientific (medical advisory board and consultant); S.A.G., R-Pharm (employee); A.N.E., R-Pharm (employee); E.G.P., R-Pharm (employee); Y.L., R-Pharm Overseas, Inc (employee); M.Y.S., R-Pharm (employee). The other authors report no conflicts.